Aspergillus infections in cystic fibrosis

Journal of Infection

Volumn 72, Issue , 2016, Pages S50-S55

  King, Jill ^a   Brunel, Shan F ^a   Warris, Adilia ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Allergic bronchopulmonary aspergillosis; Aspergillosis; Aspergillus; Aspergillus fumigatus; CFTR; Cystic fibrosis

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ITRACONAZOLE; IVACAFTOR; OMALIZUMAB; PLACEBO; POSACONAZOLE; PREDNISOLONE; VORICONAZOLE; CFTR PROTEIN, HUMAN;

ALLERGIC ASTHMA; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ALLERGIC REACTION; ANTIFUNGAL THERAPY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS BRONCHITIS; ASPERGILLUS FUMIGATUS; BRONCHIECTASIS; BRONCHITIS; CHRONIC LUNG DISEASE; CYSTIC FIBROSIS; DETERIORATION; DISEASE EXACERBATION; FUNGAL COLONIZATION; HUMAN; INNATE IMMUNITY; INVASIVE ASPERGILLOSIS; LUNG FIBROSIS; NONHUMAN; RESPIRATORY FAILURE; RESPIRATORY TRACT INFLAMMATION; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; CHRONIC DISEASE; COMPLICATION; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; LUNG; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PATHOPHYSIOLOGY; PHENOTYPE; PULMONARY ASPERGILLOSIS;

ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; CHRONIC DISEASE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; IMMUNITY, INNATE; LUNG; PHENOTYPE; PULMONARY ASPERGILLOSIS;

EID: 84969951842     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2016.04.022     Document Type: Article

References (66)

1. 1 O'Sullivan, B.P., Freedman, S.D., Cystic fibrosis. Lancet 373 (2009), 1891–1904.
2. 2 Davies, J.C., Ebdon, A.M., Orchard, C., Recent advances in the management of cystic fibrosis. Arch Dis Child 99 (2014), 1033–1036.
3. 3 Siobhan, C., Rebecca, C., Vian, R.H., UK Cystic Fibrosis Registry 2014 Annual Data Report., 2015, The Cystic Fibrosis Trust, UK.
4. 4 Cohen, T.S., Prince, A., Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 18 (2012), 509–519.
5. 5 Grasemann, H., Ratjen, F., Early lung disease in cystic fibrosis. Lancet Respir Med 1 (2013), 148–157.
6. 6 Armstead, J., Morris, J., Denning, D.W., Multi-country estimate of different manifestations of aspergillosis in cystic fibrosis. PLoS One, 9, 2014, e98502.
7. 7 Chaudhary, N., Datta, K., Askin, F.B., Staab, J.F., Marr, K.A., Cystic fibrosis transmembrane conductance regulator regulates epithelial cell response to Aspergillus and resultant pulmonary inflammation. Am J Respir Crit Care Med 185 (2012), 301–310.
8. 8 Luong, M.L., Chaparro, C., Stephenson, A., Rotstein, C., Singer, L.G., Waters, V., et al. Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantion 97 (2014), 351–357.
9. 9 Bonvillain, R.W., Valentine, V.G., Lombard, G., LaPlace, S., Dhillon, G., Wang, G., Post-operative infections in cystic fibrosis and non-cystic fibrosis patients after lung transplantation. J Heart Lung Transp 26 (2007), 890–897.
10. 10 Pihet, M., Carrere, J., Cimon, B., Chabasse, D., Delhaes, L., Symoens, F., et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis–a review. Med Mycol 47 (2009), 387–397.
11. 11 Liu, J.C., Modha, D.E., Gaillard, E.A., What is the clinical significance of filamentous fungi positive sputum cultures in patients with cystic fibrosis?. J Cyst Fibros 12 (2013), 187–193.
12. 12 Latge, J.P., Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 12 (1999), 310–350.
13. 13 Speirs, J.J., van der Ent, C.K., Beekman, J.M., Effects of Aspergillus fumigatus colonization on lung function in cystic fibrosis. Curr Opin Pulm Med 18 (2012), 632–638.
14. 14 Chotirmally, S.H., McElavaney, N.G., Fungi in the cystic fibrosis lung: bystanders or pathogens?. Int J Biochem Cell Biol 52 (2014), 161–173.
15. 15 Shoseyov, D., Brownlee, K.G., Conway, S.P., Kerem, E., Aspergillus bronchitis in cystic fibrosis. Chest 130 (2006), 222–226.
16. 16 Baxter, C.G., Dunn, G., Jones, A.M., Webb, K., Gore, R., Richardson, M.D., et al. Novel immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin Immunol 132 (2013), 560–566.
17. 17 Agarwal, R., Chakrabarti, A., Shah, A., Gupta, D., Meis, J.F., Guleria, R., et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 43 (2013), 850–873.
18. 18 Milla, C.E., Wielinski, C.L., Regelmann, W.E., Clinical significance of the recovery of Aspergillus species from the respiratory secretions of cystic fibrosis patients. Pediatr Pulmonol 21 (1996), 6–10.
19. 19 McMahon, M.A., Chotirmall, S.H., McCullagh, B., Branagan, P., McElvaney, N.G., Logan, P.M., Radiological abnormalities associated with Aspergillus colonization in a cystic fibrosis population. Eur J Radiol 81 (2012), e197–202.
20. 20 de Vrankrijker, A.M., van der Ent, C.K., van Berkhout, F.T., Stellato, R.K., Willems, R.J., Bonten, M.J., et al. Aspergillus fumigatus colonization in cystic fibrosis: implications for lung function?. Clin Microbiol Infect 17 (2011), 1381–1386.
21. 21 Jubin, V., Ranque, S., Stremler le Bel, N., Sarles, J., Dubus, J.C., Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol 45 (2010), 764–771.
22. 22 Amin, R., Dupuis, A., Aaron, S.D., Ratjen, F., The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 137 (2010), 171–176.
23. 23 Borman, A.M., Palmer, M.D., Delhaes, L., Carrere, J., Favennec, L., Ranque, S., et al. Lack of standardization in the procedures for mycological examination of sputum samples from CF patients: a possible cause for variations in the prevalence of filamentous fungi. Med Mycol 48 (2010), S88–S97.
24. 24 Coburn, B., Wang, P.W., Diaz Caballero, J., Clark, S.T., Brahma, V., Donaldson, S., et al. Lung microbiota across age and disease stage in cystic fibrosis. Sci Rep, 5, 2015, 10241.
25. 25 El-Dahr, J.M., Fink, R., Selden, R., Arruda, L.K., Platts-Mills, T.A., Heymann, P.W., Development of immune responses to Aspergillus at an early age in children with cystic fibrosis. Am J Respir Crit Care Med 150 (1994), 1513–1518.
26. 26 Fillaux, J., Bremont, F., Murris, M., Cassaing, S., Tetu, L., Segonds, C., et al. Aspergillus sensitization or carriage in cystic fibrosis patients. Pediatr Infect Dis J 33 (2014), 680–686.
27. 27 Cimon, B., Symoens, F., Zouhair, R., Chabasse, D., Nolard, N., Defontaine, A., et al. Molecular epidemiology of airway colonisation by Aspergillus fumigatus in cystic fibrosis patients. J Med Microbiol 50 (2001), 367–374.
28. 28 Delhaes, L., Monchy, S., Frealle, E., Hubans, C., Salleron, J., Leroy, S., et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community–implications for therapeutic management. PLoS One, 7, 2012, e36313.
29. 29 Gangell, C., Gard, S., Douglas, T., Park, J., de Klerk, N., Keil, T., et al. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. Clin Infect Dis 53 (2011), 425–432.
30. 30 Tirouvanziam, R., Neutrophilic inflammation as a major determinant in the progression of cystic fibrosis. Drug News Perspect 19 (2006), 609–614.
31. 31 Pillarisetti, N., Williamson, E., Linnane, B., Skoric, B., Robertson, C.F., Robinson, P., et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 184 (2011), 75–81.
32. 32 Aaron, S.D., Vandemheen, K.L., Freitag, A., Pedder, L., Camerom, W., Lavoie, A., et al. Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PLoS One, 7, 2012, e36077.
33. 33 Chrdle, A., Mustakim, S., Bright-Thomas, R.J., Baxter, C.G., Felton, T., Denning, D.W., Aspergillus bronchitis without significant immunocompromise. Ann N Y Acad Sci 1272 (2012), 73–85.
34. 34 Mastella, G., Rainisio, M., Harms, H.K., Hodson, M.E., Koch, C., Navarro, J., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 16 (2000), 464–471.
35. 35 Thia, L.P., Balfour Lynn, I.M., Diagnosing allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Paediatr Respir Rev 10 (2009), 37–42.
36. 36 Maturu, V.N., Agarwal, R., Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis. Clin Exp Allergy 45 (2015), 1765–1778.
37. 37 Fillaux, J., Bremont, F., Murris, M., Cassaing, S., Rittie, J.L., Tetu, L., et al. Assessment of Aspergillus sensitization or persistent carriage as a factor in lung function impairment in cystic fibrosis patients. Scand J Infect Dis 44 (2012), 842–847.
38. 38 Wojnarowski, C., Eichler, I., Fartner, C., Götz, M., Renner, S., Koller, D.Y., et al. Sensitization to Aspergillus fumigatus and lung function in children with cystic fibrosis. Am J Respir Crit Care Med 155 (1997), 1902–1907.
39. 39 Kraemer, R., Delosea, N., Ballinari, P., Gallati, S., Crameri, R., Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Am J Respir Crit Care Med 174 (2006), 1211–1220.
40. 40 de Almeida, M.B., Bussamra, M.H., Rodrigues, J.C., Allergic bronchopulmonary aspergillosis in paediatric cystic fibrosis patients. Paediatr Respir Rev 7 (2006), 67–72.
41. 41 Moss, R.B., Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. Curr Opin Pulm Med 16 (2010), 598–603.
42. 42 Elphick, H.E., Southern, K.W., Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev, 11, 2014, CD002204.
43. 43 Moreira, A.S., Silva, D., Ferreira, A.R., Delgado, L., Antifungal treatment in allergic bronchopulmonary aspergillosis with and without cystic fibrosis: a systematic review. Clin Exp Allergy 44 (2014), 1210–1227.
44. 44 Hilliard, T., Edwards, S., Buchdahl, R., Francis, J., Rosenthal, M., Balfour-Lynn, I., et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros 4 (2005), 215–220.
45. 45 Brodlie, M., McKean, M.C., Moss, S., Spencer, D.A., The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child 97 (2012), 604–609.
46. 46 Tanou, K., Zintzaras, E., Kaditis, A.G., Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol 49 (2014), 503–507.
47. 47 Hutcheson, P.S., Knutsen, A.P., Rejent, A.J., Slavin, R.G., A 12-year longitudinal study of Aspergillus sensitivity in patients with cystic fibrosis. Chest 110 (1996), 363–366.
48. 48 Eickmeier, O., Rieber, N., Eckrich, J., Hector, A., Graeppler-Mainka, U., Hartl, D., Immune response, diagnosis and treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis lung disease. Curr Pharm Des 19 (2013), 3669–3678.
49. 49 Zhou, Y., Song, K., Painter, R.G., Aiken, M., Reiser, J., Stanton, B.A., et al. Cystic fibrosis transmembrane conductance regulator recruitment to phagosomes in neutrophils. J Innate Imm 5 (2013), 219–230.
50. 50 Johansson, J., Vezzalini, M., Verze, G., Caldrer, S., Bolognin, S., Buffelli, M., et al. Detection of CFTR protein in human leukocytes by flow cytometry. Cytom A 85 (2014), 611–620.
51. 51 Rieber, N., Hector, A., Carevic, M., Hartl, D., Current concepts of immune dysregulation in cystic fibrosis. Int J Biochem Cell Biol 52 (2014), 108–112.
52. 52 Ratner, D., Mueller, C., Immune responses in cystic fibrosis: are they intrinsically defective?. Am J Respir Cell Mol Biol 46 (2012), 715–722.
53. 53 Dubin, P.J., McAllister, F., Kolls, J.K., Is cystic fibrosis a TH17 disease?. Inflamm Res 56 (2007), 221–227.
54. 54 Noah, T.L., Black, H.R., Cheng, P.W., Wood, R.E., Leigh, M.W., Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 175 (1997), 638–647.
55. 55 Muhlebach, M.S., Stewart, P.W., Leigh, M.W., Noah, T.L., Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 160 (1999), 186–191.
56. 56 Bonfield, T.L., Panuska, J.R., Konstan, M.W., Hilliard, K.A., Hilliard, J.B., Ghnaim, H., et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 152 (1995), 2111–2118.
57. 57 Khan, T.Z., Wagener, J.S., Bost, T., Martinez, J., Accurso, F.J., Riches, D.W., Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151 (1995), 1075–1082.
58. 58 Painter, R.G., Bonvillain, R.W., Valentine, V.G., Lombard, G.A., LaPlace, S.G., Nauseef, W.M., et al. The role of chloride anion and CFTR in killing of Pseudomonas aeruginosa by normal and CF neutrophils. J Leuk Biol 83 (2008), 1345–1353.
59. 59 Del Porto, P., Cifani, N., Guarnieri, S., Di Domenico, E.G., Mariggiò, M.A., Spadaro, F., et al. Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa. PLoS One, 6, 2011, e19970.
60. 60 Bruscia, E.M., Zhang, P.X., Satoh, A., Caputo, C., Medzhitov, R., Shenoy, A., et al. Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis. J Immunol 186 (2011), 6990–6998.
61. 61 Mueller, C., Braag, S.A., Keeler, A., Hodges, C., Drumm, M., Flotte, T.R., Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses. Am J Respir Cell Mol Bio 44 (2011), 922–929.
62. 62 Van Goor, F., Hadida, S., Grootenhuis, P.D., Burton, B., Cao, D., Neuberger, T., et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 106 (2009), 18825–18830.
63. 63 Ramsey, B.W., Davies, J., McElvaney, N.G., Tullis, E., Bell, S.C., Drevinek, P., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365 (2011), 1663–1672.
64. 64 Davies, J.C., Wainwright, C.E., Canny, G.J., Chilvers, M.A., Howenstine, M.S., Munck, A., et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 187 (2013), 1219–1225.
65. 65 Heltshe, S.L., Mayer-Hamblett, N., Burns, J.L., Khan, U., Baines, A., Ramsey, B.W., et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis 60 (2015), 703–712.
66. 66 Pohl, K., Hayes, E., Keenan, J., Henry, M., Meleady, P., Molloy, K., et al. A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy. Blood 124 (2014), 999–1009.